Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Charting the biosimilar and biobetter development pipeline


Published on

  • Login to see the comments

  • Be the first to like this

Charting the biosimilar and biobetter development pipeline

  1. 1. Charting the Biosimilar and Biobetter Development Pipeline Report Links:Charting the Biosimilar and Biobetter Development PipelineActive Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics andBiosimilars as South and Central America Emerges as a Key Growth RegionBiosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathwaysin the US to Spur Market GrowthGlobal Biosimilars Market Report: 2012 EditionBiosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low CostManufacturing Put India and China at a Strategic Advantage in Biosimilar ProductionBiosimilars: Current Situation & Future Prospects, WorldwideGlobal Biosimilar Market 2010-2014Gauging the Biosimilar Effect: will the market boom or bust?Biosimilar Drugs in Europe: threat or opportunity to innovation?Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)Biologics Price Competition and Innovation (BPCI) Act - Industry Trends Creating Demand for BiosimilarsBiosimilar development has failed to meet expectations in recent years, but that is set to change.With a new U.S. biosimilars approval pathway imminent, and the expiration of many top-selling biologics on the horizon, existingbiosimilar developers and newcomers are highly motivated to invest in the biosimilar field and are turning their attention to morecomplex biologics, such as monoclonal antibodies. Global sales of biologics are projected to reach $200bn in 2014 (from $138bn in2010), making it a potentially lucrative market for biosimilar developers.Originator, generics, and biosimilar companies alike need to be informed about the latest development trends and to know thelikely patent expiration of marketed products and status of products in development. However, market intelligence has been widelydispersed, making it very difficult for companies to assess potential competition and areas of opportunity, until now.FirstWord has gathered the very latest intelligence from BIOPHARMA, the Orange Book, literature, industry associations, companywebsites, and many other secondary sources to provide a single, authoritative guide to currently marketed and in-developmentbiosimilar products.Report OverviewIn Charting the Biosimilar and Biobetter Development Pipeline , you’ll find details of currently marketed biosimilar and biobetterdrugs, and all biosimilar and biobetter drugs known to be in clinical development.Through more than 60 intuitive tables and charts, you will receive unique insights into high-level trends and significant
  2. 2. developments, and can easily drill down to details of a specific product or therapeutic area.Need to know when Drug X will expire? Expiration dates for reference products draw on analysis of products, active agents, andmanufacturing processes to go far beyond the Orange Book.Need to know who is developing biobetters for interferons? Access a complete list with generic and candidate names, developers,reference products, and earliest possible EU/US launch dates.The report’s author has also included concise commentary throughout, providing valuable context and key insights.For a complete guide to biosimilars at your fingertips, download Charting the Biosimilar and Biobetter Development Pipeline today.Key Report FeaturesMore than 60 exclusive tables and charts, offering a complete and illuminating view of the biosimilar pipelineUp-to-the-minute details of ALL biosimilars/biobetters known to be in development in US and EU markets, with their developmentstatus and earliest potential launch datesInformation on international biogenerics that may seek approval as biosimilars/biobetters in US and EU marketsComprehensive list of reference products, with key sales data and expected patent expiration datesDetailed analysis of the biosimilar pipeline and market by reference products, therapeutic area, drug class, and compound classReports showing the most active companies, regions, and countriesInsights into areas of most intense competition and greatest potential opportunityConcise commentary highlighting key findings, and providing valuable market intelligenceDefinitions of key terms and conceptsKey BenefitsUnderstand the universe of biosimilar and biobetter developmentGet the complete picture of all products in the biosimilar pipelineKnow the latest status on specific biosimilar andbiobetter products of interest to youRead about the most significant developments in every therapeutic areaDiscover the levels of potential biosimilar and biobetter competition by therapy area and drug classAnalyze the size of the threat to your company’s biologic portfolioLearn which companies are potential future competitorsKey Questions AnsweredWhen is the earliest potential launch for “Biosimilar X”?What biosimilars are being developed in each therapeutic area, drug class, and compound class?Which reference products are most targeted by biosimilar and biobetter developers?Is the reference product sales value the key factor shaping biosimilar development priorities?Which therapy areas are going to experience the most and fewest biosimilar entries?Which companies are most active in the biosimilar and biobetter arena?Which biosimilar companies have been most successful in getting their products onto the market?How many new biosimilars will be on the market by 2014?Who Should Read This Report?Strategic executives at originator, generic, and biosimilar/biobetter development companies, especially in:Sales and MarketingRegulatory AffairsIP and Patent AffairsMarket ResearchResearch & DevelopmentBusiness DevelopmentMedical CommunicationsTable of Contents :Executive summaryIntroductionDefinitions and methodologyScope and coverageGlossaryMethodologyPatentsIndexing by indicationIndexing by phase of developmentNomenclature
  3. 3. Reference productsTop20 Reference ProductsBiosimilars in developmentBiosimilars by earliest potential launch date — US & EUBiosimilars by class and earliest potential launch date in the US (total number)Biosimilars by class and earliest potential launch date in the EU (total number)Biosimilar developers countries and regionsBiosimilars in development by drug classLeading biosimilar companies - number of biosimilar products in portfolioBiosimilar development pipelines by compound class and therapy areaBiosimilar development pipelines by compound classImmunomodulatorsInterferonsmAb ImmunomodulatorsCytotoxic mAbsErythropoietinG-CSFInsulinsOther Hormones (excluding insulins)Biosimilar development pipelines by therapy areaEndocrine and metabolic disordersHaematologyInfectious and Parasitic DiseaseMusculoskeletal disordersNeurologyNeuromuscular diseasesObstetrics/gynaecologyOncologyOphthalmologyBiobetters in developmentBiobetter developments by compound class and therapy areaBiobetter development by therapy area and stageBiobetters by class and earliest potential launch in the USBiobetters by class and earliest potential launch in the EUBiobetter developers by compound classBiobetter development pipeline by compound classImmunomodulatorsInterferonsmAb ImmunomodulatorsCytotoxic mAbsErythropoietinsOthers (Enzymes, Blood Clotting Factors)Other Hormones (excluding insulins)Biobetter development pipeline by therapy areaAutoimmune diseaseAutoinflammatory diseaseCardiovascular diseasesDermatologyEndocrine and metabolic disorderHaematologyInfectious and parasitic diseaseMusculoskeletal disordersNeurologyObstetrics/gynaecologyOncologyRespiratory diseaseWound careProduct profilesRelated Keywords : Charting , Biosimilar,Biobetter, Development, PipelineFor More details about above & other Reports plz contact
  4. 4. Contact: Marketing teamMob.No.918149852585Email: , discount@aarkstore.comURL: http://www.aarkstore.com